Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Wednesday, 25'th Dec 2024
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
04:05pm, Monday, 23'rd Dec 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Mor
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
02:46pm, Monday, 23'rd Dec 2024
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
11:13am, Monday, 23'rd Dec 2024
Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
04:30am, Sunday, 22'nd Dec 2024
Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in c
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
06:16pm, Friday, 20'th Dec 2024
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday. The post Vertex Wins An Early Approval; Why It Might Not Move Vertex
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
04:01pm, Friday, 20'th Dec 2024
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
03:46pm, Friday, 20'th Dec 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaf
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
Cramer's Mad Dash: Vertex Pharmaceuticals
10:12am, Friday, 20'th Dec 2024
CNBC's Jim Cramer delivers his daily Mad Dash.
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
08:00am, Friday, 20'th Dec 2024
Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study. The post Is Vertex Stock A Sell After Pain Drug Whiffs In Mid
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot
02:11pm, Thursday, 19'th Dec 2024
The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
01:06pm, Thursday, 19'th Dec 2024
On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower ba
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years
11:23am, Thursday, 19'th Dec 2024
Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study.
